Overview

The therapeutic landscape for PCSK9 inhibitors is rapidly evolving; therefore, pharmacists require education on the safety and efficacy of PCSK9 inhibitors for the treatment of hyperlipidemia. This curriculum will assist pharmacists in optimizing hyperlipidemia care, as well as enable them to provide both prescribers and patients with pertinent safety and efficacy data about this class of drugs. Expanding the use of PCSK9 inhibitors is warranted to improve clinical outcomes in patients with hyperlipidemia, and the various activities in this series as well as the video vignettes will highlight key takeaways to use in practice.